Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA) (CHS-0214-02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02115750
Recruitment Status : Completed
First Posted : April 16, 2014
Results First Posted : June 26, 2019
Last Update Posted : June 26, 2019
Sponsor:
Collaborator:
Daiichi Sankyo Co., Ltd.
Information provided by (Responsible Party):
Coherus Biosciences, Inc.

Brief Summary:

This is a two part study comparing CHS-0214 to Enbrel in patients with active rheumatoid arthritis and an inadequate response with Methotrexate (MTX) who are naive to biologic therapies.

Pt.1 is a 24-week randomized, double-blind, active-control, parallel-group, multi-center global study. The primary end point is 20% improvement in American College of Rheumatology criteria (ACR-20) at week 24. Comparing CHS-0214 to Enbrel for efficacy and safety.

Pt. 2 is an open-label single arm study in which patients with at least an ACR-20 response receive CHS-0214. Continued response and safety will be evaluated.


Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: Etanercept Drug: CHS-0214 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 647 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate
Study Start Date : May 2014
Actual Primary Completion Date : October 2015
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Etanercept

Arm Intervention/treatment
Active Comparator: Enbrel (etanercept)
Enbrel 50mg weekly times 24 weeks.
Drug: Etanercept
Head-to-head comparison
Other Names:
  • Enbrel
  • European Enbrel

Experimental: CHS-0214
CHS-0214 50mg weekly times 24 weeks.
Drug: CHS-0214



Primary Outcome Measures :
  1. ACR-20 - 20% Improvement According to American College of Rheumatology Criteria [ Time Frame: 24-weeks ]
    The primary efficacy endpoint in Part 1 was the percentage of subjects who achieved ACR20 (20% improvement according to American College of Rheumatology criteria) at week 24 compared to baseline (last non-missing value prior to first dose). Subjects were considered an ACR20 responder if when compared to baseline (last non-missing value prior to first dose), they achieved a 20% decrease in SJC (Swollen joint count), 20% decrease in TJC (Tender joint count), and 20% improvement in 3 of the following 5 measures: high sensitivity C reactive protein(hs-CRP), Health Assessment Questionnaire Disability Index(HAQ-DI), subjects global assessment of pain(SPA, VAS), subject's global assessment of disease activity(SGA-VAS), physician's global assessment of disease activity(PGA-VAS)


Secondary Outcome Measures :
  1. ACR20 - (20% Improvement According to American College of Rheumatology Criteria) at Weeks 4, 8, 12, and 18 [ Time Frame: Weeks 4, 8, 12 and 18 ]

    Subjects were considered an ACR20 responder if, when compared to baseline (last non-missing value prior to first dose), they achieved a 20% decrease in SJC, 20% decrease in TJC, and 20% improvement in 3 of the following 5 measures:

    • High sensitivity C-reactive protein (hs-CRP);
    • Health Assessment Questionnaire-Disability Index (HAQ-DI);
    • Subject's global assessment of pain (ie, subject's pain assessment [SPA]-visual analog scale [VAS]);
    • Subject's global assessment of disease activity (SGA-VAS); and
    • Physician's global assessment of disease activity (PGA-VAS).

    In these calculations, the percent change from baseline to endpoint was used to determine ACR20. For percentage change calculations, results were rounded to 5 decimal places prior to comparing to the threshold of 20%.For SJCs and TJCs, the assessment of efficacy was based on mean change from baseline (last non-missing value prior to first dose evaluation).


  2. Summary of Change in Tender Joint Count (TJC) by Study Visit [ Time Frame: Weeks 4,8,12,18,24,28,36,48 ]
    The average percent improvement from baseline in individual ACR response criteria: TJC (Tender joint count) the 66/68 Joint Count evaluates 68 joints for tenderness and pain with movement. The temporomandibular, sternoclavicular, acromioclavicular, shoulder, elbow, wrist, metacarpophalangeal (MCP), proximal interphalangeal (PIP), distal interphalangeal (DIP), hip, knee, ankle, tarsus, metatarsophalangeal (MTP), and interphalangeal of the feet are included in this joint count. Hip joints can be evaluated for tenderness.

  3. Summary of Change in Swollen Joint Count (SJC) by Study Visit [ Time Frame: Weeks 4,8,12,18,24,28,36,48 ]
    The 66/68 Joint Count evaluates 66 joints for swelling. The temporomandibular, sternoclavicular, acromioclavicular, shoulder, elbow, wrist, metacarpophalangeal (MCP), proximal interphalangeal (PIP), distal interphalangeal (DIP), hip, knee, ankle, tarsus, metatarsophalangeal (MTP), and interphalangeal of the feet are included in this joint count.

  4. Summary of Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) by Study Visit [ Time Frame: Weeks 4,8,12,18,24,28,36,48 ]
    HAQ-DI - Scales for each question range from 0-3 (0=without any difficulty; 1=with some difficulty; 2=with much difficulty; 3=Unable to do). The "total" for each category is determined by the highest score (greatest difficulty) for that category. The score for the disability index is the mean of the eight category scores. If more than 2 of the categories or 25% are missing, the scale won't be scored. If fewer than 2 or the categories are missing, the sum of the categories was divided by the number of answered categories.

  5. Summary of Change in Subject's Pain Assessment - Visual Analog Scale (SPA-VAS) by Study Visit [ Time Frame: Weeks 4,8,12,18,24,28,36,48 ]
    The score range for the SPA-VAS is 0-100 millimeters. One total score was reported for each assessment, no subscales exist. A lower score on the left side represents a better outcome (less pain) and the higher score is on the right side representing a worse outcome (more pain).

  6. Summary of Change in Physician's Global Assessment- Visual Assessment Scale (PGA-VAS) by Study Visit [ Time Frame: Weeks 4,8,12,18,24,28,36,48 ]
    The score range for PGA-VAS is 0-100 millimeters. The patient's assessment of disease activity - with the lowest score on the left side representing "none" to the highest score on the right side representing "extremely active".



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female adults
  • RA (Rheumatoid Arthritis) diagnosis for 6 months
  • On stable dose of MTX of 8mg to 25mg per week
  • Active disease: greater than 6 tender joints, greater than 6 swollen joints, C-reactive protein (CRP) greater than or equal to 0.5mg/dL, and disease activity score (DAS) with 28 joints (DAS28-CRP(4)) greater than or equal to 3.2

Exclusion Criteria:

  • Use of prednisone greater than 10mg/day
  • Use of greater than one non-steroidal anti-inflammatory drug (NSAID)
  • Use of biologic therapies for any cause
  • Chemistry and hematology values outside protocol specified range
  • Positive QuantiFERON-tuberculosis (TB) Gold Test
  • Evidence of active lung disease on chest x-ray
  • Major systemic infections
  • Presence of significant comorbid conditions
  • Known allergy to latex
  • Women who are pregnant or nursing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02115750


  Show 141 Study Locations
Sponsors and Collaborators
Coherus Biosciences, Inc.
Daiichi Sankyo Co., Ltd.
Investigators
Layout table for investigator information
Study Director: Barbara K Finck, M.D. Coherus Biosciences, Inc.

Layout table for additonal information
Responsible Party: Coherus Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT02115750     History of Changes
Other Study ID Numbers: CHS-0214-02
First Posted: April 16, 2014    Key Record Dates
Results First Posted: June 26, 2019
Last Update Posted: June 26, 2019
Last Verified: June 2019
Keywords provided by Coherus Biosciences, Inc.:
CHS-0214
Enbrel
RA
Biosimilar
Etanercept
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Etanercept
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gastrointestinal Agents
Immunosuppressive Agents
Immunologic Factors